Amgen Infergen Cleared For Hepatitis C Retreatment Following Relapse
Amgen's Infergen has expanded its labeling for use in the subsequent treatment of hepatitis C patients who relapse following initial treatment with interferon alfa-2b or Infergen.
You may also be interested in...
Product.......... Humate-P (S, V) Ingredient....... Antihemophilic factor/von Willebrand factor complex (human) Sponsor.......... Centeon Pharma GmbH Indication....... New indication for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate Date Approved.... 4/1/1999 Application No... 96-1099 Footnote......... Standard review; Orphan drug
Two FDA decisions about biologics applications in line for early approval in 1999, ReFacto and Rebif, could hinge on orphan exclusivity deliberations.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011